Four ministries and commissions jointly organize and implement the construction of biomedical contract R & D and production service platform

Recently, the national development and Reform Commission, the Ministry of industry and information technology, the national health and Health Commission and the State Drug Administration jointly issued the notice on organizing and implementing the construction of biomedical contract R & D and production service platform (hereinafter referred to as the notice) It is planned to organize and implement the construction of biomedical contract R & D and production service platform (hereinafter referred to as the construction special project) during the 13th Five Year Plan period ”）To focus on supporting the construction of a number of high-level and international comprehensive biomedical contract R & D and production service platforms, and strive to improve the capacity of biomedical R & D and production service The notice stressed that it is necessary to effectively support the R & D and industrialization of innovative drugs through special implementation, and strive to reach 100 per year The ability to provide services for the development of more than new drugs; to improve the scale and intensive level of drug production and the efficiency of the whole industry development, to support the development of a number of innovative and Entrepreneurial Small and medium-sized enterprises; to promote the further high-quality agglomeration of regional biomedical industry, and to accelerate the cultivation of a number of world-class biomedical industry clusters The main task of the construction project is to strengthen the advantageous enterprises, enhance the innovation ability and promote the agglomeration development We need to promote advantageous enterprises to continuously improve the level of efficient R & D and advanced manufacturing services, expand service areas and improve service systems, build a number of professional contract R & D and production service enterprises with strong comprehensive strength and international competitiveness, and provide strong support for deepening the implementation of drug review and approval system reform; guide contract R & D and production service enterprises to focus on China's drug R & D The key links of the production chain need to be improved urgently We need to break through a number of common technologies, reduce R & D and production costs, substantially improve the development efficiency of the biomedical industry, and accelerate the integration with the international advanced level We need to give full play to the radiation driving effect of "point to area" of the biomedical contract R & D and production service enterprises, stimulate innovation and entrepreneurship, and promote the continuous collection of talents, funds and other elements, so as to strengthen The cooperation and linkage of all links of the chemical industry chain will improve the level of industrial division and coordination within the region, build a good industrial development ecology, and accelerate the formation of a number of biopharmaceutical industry clusters with international influence According to the notice, it will focus on supporting the R & D service and production service of biomedical contract Focus on supporting the advantageous enterprises with strong industry influence, high standard quality assurance system, and sound public service mechanism, build a contract R & D service platform in the pharmaceutical research, preclinical safety evaluation, new drug clinical research and other subdivisions, give priority to supporting a comprehensive integrated contract R & D service platform that can provide multi link and international services, and focus on supporting innovative pharmaceutical students The construction of contract production service platforms, such as production process development and industrialization, and large-scale commissioned processing of listed drugs, gives priority to supporting the large-scale and specialized contract production service platform that grasps the core technology of drug production, quality system and environmental health and safety (EHS) system and is in line with international standards, with sound public service mechanism.